Equities research analysts expect Scpharmaceuticals Inc (NASDAQ:SCPH) to report ($0.58) earnings per share (EPS) for the current quarter, Zacks reports. Zero analysts have made estimates for Scpharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.57) and the lowest estimate coming in at ($0.59). The firm is scheduled to issue its next earnings report on Monday, August 13th.
According to Zacks, analysts expect that Scpharmaceuticals will report full-year earnings of ($2.22) per share for the current fiscal year, with EPS estimates ranging from ($2.35) to ($2.09). For the next financial year, analysts forecast that the business will report earnings of ($2.40) per share, with EPS estimates ranging from ($2.48) to ($2.31). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Scpharmaceuticals.
A number of equities analysts recently commented on SCPH shares. Zacks Investment Research downgraded Scpharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, May 11th. Jefferies Financial Group dropped their price objective on Scpharmaceuticals from $26.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, June 14th. ValuEngine upgraded Scpharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. BMO Capital Markets dropped their price objective on Scpharmaceuticals from $24.00 to $14.00 and set an “outperform” rating for the company in a research note on Thursday, June 14th. Finally, Leerink Swann dropped their price objective on Scpharmaceuticals from $20.00 to $12.00 and set an “outperform” rating for the company in a research note on Thursday, June 14th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $12.67.
A number of institutional investors and hedge funds have recently modified their holdings of SCPH. Goldman Sachs Group Inc. bought a new stake in shares of Scpharmaceuticals during the 4th quarter valued at $653,000. Citigroup Inc. acquired a new stake in Scpharmaceuticals during the first quarter worth approximately $481,000. BlackRock Inc. grew its stake in Scpharmaceuticals by 21,048.8% during the first quarter. BlackRock Inc. now owns 288,469 shares of the company’s stock worth $3,577,000 after purchasing an additional 287,105 shares during the period. Schwab Charles Investment Management Inc. acquired a new stake in Scpharmaceuticals during the first quarter worth approximately $167,000. Finally, Millennium Management LLC acquired a new stake in Scpharmaceuticals during the fourth quarter worth approximately $462,000. Hedge funds and other institutional investors own 44.74% of the company’s stock.
Scpharmaceuticals traded up $0.01, reaching $4.59, on Friday, according to Marketbeat.com. The company’s stock had a trading volume of 52,710 shares, compared to its average volume of 48,005. Scpharmaceuticals has a twelve month low of $4.32 and a twelve month high of $18.17. The company has a current ratio of 19.23, a quick ratio of 19.23 and a debt-to-equity ratio of 0.10. The company has a market capitalization of $84.92 million and a price-to-earnings ratio of -0.57.
scPharmaceuticals Inc, a clinical-stage pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix, a drug-device combination product that is under development for treatment of worsening or decompensated heart failure outside of the inpatient setting.
See Also: Google Finance Portfolio Tips and Tricks
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.